Robert Bessler

Director Robert Bessler sells 894,337 shares at $10.13 under 10b5-1 plan; holdings fall 57.7% to 656.6K shares

Robert Bessler, a director at LifeStance Health Group, Inc., executed 2 separate sales totaling 894,337 shares for $9,059,633.81 at a blended average price of $10.13 on 2026-06-26. His post-transaction holdings fell to 656,560 shares, a net reduction of 57.7% versus his pre-transaction position of 1,550,897 shares. This transaction is part of a pre-arranged 10b5-1 trading plan, meaning it was scheduled rather than discretionary. The current stock price stands at $10.71, slightly below the 52-week high of $10.89, with the stock up 38.9% over 30 days and 68.1% over 90 days. At this ticker, Bessler's two prior sales on 2026-05-12 each posted a 30-day return of +7.4%. The scheduled nature of this sale precludes any characterization based on timing; investors should note the substantial reduction in Bessler's personal stake.

Director Bessler sells 575,034 shares of LFST at $8.02 for $4.6M, retaining 1.10M shares near 52-week high.

Director Robert Bessler sold 575,034 shares at $8.02, generating $4,611,772.68 in proceeds, while the stock's current price of $7.89 sits -11.2% below its 52-week high of $8.89. The sale occurred against a backdrop of notable recent price strength — the stock gained +21.2% over the prior 30 days — placing the transaction near the upper end of LFST's trading range. Despite the sizable disposal, Bessler retains 1,103,729 shares post-transaction, indicating continued meaningful economic exposure to the company. Investors may watch whether this sale, executed close to the 52-week high amid a strong near-term rally, reflects a near-peak disposition, particularly given LFST's elevated P/E of 131.50 relative to its $14.2M net income on $403.5M in quarterly revenue.